Moderna has started a Phase 1 trial of an experimental vaccine against Bundibugyo ebolavirus in Canada. The first participant received the mRNA-1469 vaccine on August 3 at a site in Truro, Nova Scotia. The trial comes as the virus continues spreading across several provinces in the Democratic Republic of the Congo. The World Health Organization has classified the outbreak as a public health emergency of international concern.

Michigan health officials have confirmed two deaths connected to the state’s 2026 cyclosporiasis outbreak. The Michigan Department of Health and Human Services reported 11,234 cases as of Aug. 3. The state also recorded 193 hospitalizations through July 30. Both patients had serious underlying medical conditions. Officials said cyclosporiasis and dehydration may have affected those conditions, but they released no additional personal information.

The surge placed further pressure on surveillance, treatment and community response operations. Cases now span 49 health zones in Ituri, North Kivu, South Kivu, Haut-Uélé and Tshopo. Thirty-three zones reported active transmission during the latest seven-day period. They registered 641 cases and 282 deaths. Ituri remained the outbreak’s center, with 3,176 infections, or 88% of the national total. The World Health Organization rates the risk inside DR Congo as very high. It also considers the threat high for Uganda and other countries bordering affected areas. Contact tracing falls short of needs.

KINSHASA, DEMOCRATIC REPUBLIC OF THE CONGO / RankWire.AI / – The Democratic Republic of the…

BUNIA, DEMOCRATIC REPUBLIC OF THE CONGO / RankWire.AI / – The World Health Organization reported…

ITURI, DEMOCRATIC REPUBLIC OF THE CONGO / RankWire.AI / – The Democratic Republic of the Congo…